Recommendation ID
TA283/1
Question
NICE concluded that further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with macular oedema secondary to retinal vein occlusion should be conducted.
Any explanatory notes
(if applicable)
None.

Source guidance details

Comes from guidance
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion
Number
TA283
Date issued
May 2013

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No  
Last Reviewed 13/06/2013